Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 13,585 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatoses Clear all
Completed No phase listed Observational Accepts healthy volunteers

Identifying Genetic Determinants of Eczema Herpeticum and Other Viral Infections in Individuals With Atopic Dermatitis

NCT00515047
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Months to 80 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
7
States / cities
La Jolla, California • Denver, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 22, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease

NCT07685938
View directory record Official record
Conditions
Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor, Thoracic Cancer, Thoracic Neoplasms
Interventions
Atorvastatin and Lisinopril, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma

NCT00004148
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant vaccinia-B7.1 vaccine
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 22, 2026, 4:15 PM EDT
Not listed Not applicable Interventional

Sebacia Postmarket Study of Real-World Use

NCT03818555
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sebacia Microparticles Treatment
Other
Lead sponsor
Sebacia, Inc.
Industry
Eligibility
12 Years to 45 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Murfreesboro, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

NCT00243685
View directory record Official record
Conditions
Breast Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Sarcoma, Soft Tissue
Interventions
Laboratory Assay, Mick Assay
Other
Lead sponsor
Pierian Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
3
States / cities
Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 22, 2026, 4:15 PM EDT
Completed No phase listed Observational

A Non-drug Study Profiling Cutaneous Lupus

NCT01923415
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 22, 2026, 4:15 PM EDT
Active, not recruiting Phase 2 Interventional

Intralesional Gardasil-9 for the Treatment of Recalcitrant Warts

NCT07806617
View directory record Official record
Conditions
Warts, Verruca (Warts), Verruca Vulgaris
Interventions
9-valent human papillomavirus vaccine, Sterile Saline
Biological · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

NCT00014391
View directory record Official record
Conditions
Cancer
Interventions
palivizumab, ribavirin
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors

NCT03304587
View directory record Official record
Conditions
Breast Cancer
Interventions
Polysomnography (PSG), Rectal thermistor 400 Series, Bright blue-green light, Dim red light, Digital foot candle datalogging light meter, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression, Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function, Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiological Studies - Depression, Montreal Cognitive Assessment (MoCA), European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30), Daily Log
Diagnostic Test · Other
Lead sponsor
Michigan State University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

NCT03551821
View directory record Official record
Conditions
Alopecia Areata, Alopecia Totalis, Alopecia Universalis
Interventions
ATI-50002
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boynton Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Not applicable Interventional

Cancer, Obesity/Overweight and Insomnia Study

NCT03542604
View directory record Official record
Conditions
Breast Cancer, Overweight and Obesity, Insomnia
Interventions
Cognitive Behavioral Therapy for Insomnia, Sleep Education
Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Early Phase 1 Interventional

Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes

NCT00360152
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Fine needle aspiration biopsy (FNAB), Sentinel Lymph Node Biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Interventions
Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
Drug · Other
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

NIR-Guided Sentinel Lymph Node Mapping in Melanoma

NCT01121718
View directory record Official record
Conditions
Melanoma
Interventions
ICG Intervention
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2017 · Synced Oct 22, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

NCT01307618
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Skin Melanoma
Interventions
NA17.A2 Peptide Vaccine, Recombinant MAGE-3.1 Antigen, Recombinant Interleukin-12, MART-1 Antigen, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

NCT04656418
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CSL312, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 22, 2026, 4:15 PM EDT
Not listed Phase 3 Interventional

Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System

NCT00006132
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 28 Days
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 4 Interventional Results available

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

NCT01794793
View directory record Official record
Conditions
Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors, Ectopic ACTH Secreting (EAS) Tumors, Dumping Syndrome, Prostate Cancer, Melanoma Negative for bRAF, Melanoma Negative for nRAS
Interventions
Pasireotide, Cabergoline, Pasireotide LAR
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

NCT02816021
View directory record Official record
Conditions
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Interventions
Azacitidine, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 22, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00023647
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Synchrotope TA2M
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Oct 22, 2026, 4:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers

NCT02399826
View directory record Official record
Conditions
Diabetic Foot, Foot Ulcer; Diabetic
Interventions
Offloading, Dressing Application
Device · Procedure
Lead sponsor
Lower Extremity Institute for Research and Therapy
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
3
States / cities
Canfield, Ohio • Danville, Virginia • Troutville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 22, 2026, 4:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

NCT07109726
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Solid Tumor, Cervical Cancer
Interventions
TER-2013, Fulvestrant injection
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 22, 2026, 4:15 PM EDT